Drug therapy in chronic heart failure

Postgraduate Medical Journal

Volumn 79, Issue 937, 2003, Pages 634-642

  McKenzie, D B ^a   Cowley, A J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDRALAZINE; ISOSORBIDE DINITRATE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOLAZONE; METOPROLOL; OMAPATRILAT; PLACEBO; PRAZOSIN; QUINIDINE; SINORPHAN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT;

ADRENERGIC SYSTEM; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART LEFT VENTRICLE; HUMAN; HYPERKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; DIGOXIN; DIURETICS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; SPIRONOLACTONE; VASODILATOR AGENTS;

EID: 0348140991     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.937.634     Document Type: Review

References (89)

1. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83:596-602.
2. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study [comment]. Eur Heart J 1999;20:421-8.
3. Remme WJ, Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
4. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948-55.
5. Varela-Roman A, Gonzalez-Juanatey JR, Basante P, et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart 2002;88:249-54.
6. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
8. McMurray J. Heart failure: we need more trials in typical patients. Eur Heart J 2000;21:699-700.
9. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. European Journal of Heart Failure 2001;3:283-91.
10. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
11. Francis GS, Goldsmith SR, Cohn JN. Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J 1982;104(4 pt 1):725-31.
12. Viquerat CE, Daly P, Swedberg K, et al. Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. Am J Med 1985;78:455-60.
13. Sackner-Bernstein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with adrenergic blockade [erratum appears in JAMA 1996;275:686]. JAMA 1995;274:1462-7.
14. Frishman WH. Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease: current concepts. Circulation 1983;67(6 pt 2):111-8.
15. Mann DL, Kent RL, Parsons B, et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
16. Blue L, Lang E, McMurray JJ, et al. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ 2001;323:715-8.
17. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet 1999;354:1077-83.
18. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure [comment]. N Engl J Med 1995;333:1190-5.
19. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [comment] [erratum appears in BMJ 2002;324:141]. BMJ 2002;324:71-86.
20. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) [comment]. JAMA 1991;265:3255-64.
21. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease [comment] [erratum appears in Journal of Cardiac Failure 1998;4:367]. Journal of Cardiac Failure 1997;3:249-54.
22. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA) [comment]. Lancet 1994;344:493-8.
23. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group [comment]. N Engl J Med 1999;341:857-65.
24. Department of Health. The national service framework for coronary heart disease. Available at: www.doh.gov.uk/nsf/coronary.htm, 2000.
25. Taylor SH. Refocus on diuretics in the treatment of heart failure. Eur Heart J 1995;16(suppl F):7-15.
26. Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. British Heart Journal 1987;57:17-22.
27. Kaddoura S, Patel D, Parameshwar J, et al. Objective assessment of the response to treatment of severe heart failure using a 9-minute walk test on a patient-powered treadmill. Journal of Cardiac Failure 1996;2:133-9.
28. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
29. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group [comment]. N Engl J Med 1996;335:1107-14.
30. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993;22:955-62.
31. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993;329:1-7.
32. The Digitolis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
33. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-91.
34. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
35. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-6.
36. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
37. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
38. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8.
39. Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59:7-10.
40. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Cir Res 1997;80:219-27.
41. Petrie MC, Padmanabhan N, McDonald JE, et al. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001;37:1056-61.
42. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995;26:438-45.
43. Lang RM, Elkayam U, Yellen LG, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol 1997;30:983-91.
44. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) [comment]. Lancet 1997;349:747-52.
45. Tsuyuki RT, Yusuf S, Rouleau JL, et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997;13:1166-74.
46. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II [comment]. Lancet 2000;355:1582-7.
47. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med 2001 ;345:1667-75.
48. Cohn JN. Lessons learned from the valsartan-heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. Am J Cardiol 2002;90:992-3.
49. Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 1999;83:477-81.
50. Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure -assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. Journal of Cardiac Failure 1999;5:276-82.
51. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
52. Anonymous. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
53. Anonymous. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
54. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-6.
55. Waagstein F, Wahlqvist I, Andersson B, et al. Metoprolol prevents left ventricular dilatation and increases exercise ejection fraction to the same extent in idiopathic and ischemic cardiomyopathy. Eur Heart J 1998;19(suppl):307(abstract).
56. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-8.
57. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
58. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
59. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol, 1997;79:794-8.
60. McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. European Journal of Heart Failure 2001;3:495-502.
61. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med 2001;110(suppl 7A):81S-94S.
62. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators [comment]. N Engl J Med 1999;341:709-17.
63. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997;96:856-63.
64. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.[comment]. N Engl J Med 1991;325:1468-75.
65. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators [comment]. British Heart Journal 1994;72:226-30.
66. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators [comment]. N Engl J Med 1998;339:1810-6.
67. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure [comment] [erratum appears in Lancet 1990;336:698]. Lancet 1990;336:1-6.
68. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinon on survival in chronic heart failure: preliminary results of the PROFILE study [abstract]. Circulation 1993;88(suppl 1):1-301.
69. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349:971-7.
70. Northridge DB, Jardine AG, Alabaster CT, et al. Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet 1989;2:591-3.
71. Northridge DB, Currie PF, Newby DE, et al. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. European Journal of Heart Failure 1999;1:67-72.
72. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet 1998;351:1657-8.
73. McClean DR, Ikram H, Garlick AH, et al. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 2000;36:479-86.
74. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial [comment] [erratum appears in Lancet 2000;356:1774]. Lancet 2000;356:615-20.
75. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-6.
76. McMurray JJ, Ray SG, Abdullah I, et al. Plasma endothelin in chronic heart failure. Circulation 1992;85:1374-9.
77. Galatius-Jensen S, Wroblewski H, Emmeluth C, et al. Plasma endothelin in congestive heart failure: a predictor of cardiac death? Journal of Cardiac Failure 1996;2:71-6.
78. Lave MP, McMurray JJ. Endothelin in heart failure: a promising therapeutic target? Heart 1997;77:93-4.
79. Petrie MC, McClure SJ, Love MP, et al. Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin-1. European Journal of Heart Failure 1999;1:25-9.
80. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1- mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
81. Cowburn PJ, Cleland JG, McArthur JD, et al. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet 1998;352:201-2.
82. Torre-Amione G, Young JB, Durand J, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001;103:973-80.
83. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure [comment]. Circulation 2000;101:2922-7.
84. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85:195-7.
85. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80.
86. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-44.
87. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23.
88. Richardson LG, Rocks M. Women and heart failure. Heart Lung 2001;30:87-97.
89. Walker S, Levy TM, Coats AJS, et al. Biventricular pacing in congestive cardiac failure. Eur Heart J 2000;21:884-9.